A multi-institution study found that deletions of a certain tumor-suppressor gene in diffuse gliomas—the most common primary brain tumors—display distinct patterns, signify a poor prognosis in patients, and should be included in models predicting the clinical behavior of these tumors.
NeOnc Technologies Holdings Inc., a clinical-stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from the California Investment Forum for its innovations in medical technology related to the treatment of brain and central nervous system diseases.
